Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.015 SEK | -11.56% | -19.05% | -47.58% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2023 | 35.2M 3.22M | Sales 2024 * | 105M 9.62M | Capitalization | 448M 41.05M |
---|---|---|---|---|---|
Net income 2023 | -249M -22.79M | Net income 2024 * | -223M -20.41M | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.13M | Net cash position 2024 * | 208M 19.01M | EV / Sales 2024 * | 2.29 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-1.83
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | -13.04% | ||
1 week | -19.05% | ||
Current month | -38.23% | ||
1 month | -7.32% | ||
3 months | -42.49% | ||
6 months | -44.13% | ||
Current year | -47.58% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Klaas Bakker
CTO | Chief Tech/Sci/R&D Officer | 42 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 4.015 | -11.56% | 1 417 925 |
24-04-18 | 4.54 | +1.57% | 617,626 |
24-04-17 | 4.47 | -6.19% | 710,498 |
24-04-16 | 4.765 | -8.89% | 1,649,095 |
24-04-15 | 5.23 | +5.44% | 1,116,048 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 10:25 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.58% | 41.04M | |
-2.65% | 102B | |
+2.23% | 96.07B | |
-1.46% | 21.66B | |
-17.24% | 20.77B | |
-6.96% | 18.53B | |
-40.31% | 16.91B | |
-28.21% | 13.79B | |
-0.09% | 13.33B | |
+20.28% | 10.94B |
- Stock Market
- Equities
- ONCO Stock